Fed’s Powell opens door to potential rate cuts at Jackson Hole
Simon Stertzer, a director at BioCardia, Inc. (NASDAQ:BCDA), has increased his stake in the company with recent stock purchases totaling $88,064. The micro-cap company, currently valued at $11.55 million, has seen its stock surge 20% in the past week. According to InvestingPro analysis, the stock is trading close to its Fair Value. According to a recent SEC filing, Stertzer acquired 38,289 shares of BioCardia common stock over two transactions on March 3 and March 4, 2025. The shares were purchased at a weighted average price of $2.30 per share, with prices ranging from $2.13 to $2.50 per share on March 3 and $2.34 to $2.50 per share on March 4.
Post-transaction, Stertzer now directly owns 56,138 shares. Additionally, he holds indirect ownership through various trusts and entities, including the Stertzer Family Trust and Windrock Enterprises L.L.C., bringing his total indirect holdings to 77,462 shares.
In other recent news, BioCardia, Inc. has announced the completion of its Phase 3 CardiAMP Heart Failure study’s primary outcomes data verification and freezing process. This trial, one of the largest of its kind for ischemic heart failure patients with reduced ejection fraction, involved 115 randomized participants. The data has been transferred to the Statistical Data Analysis Center core laboratory for further analysis, with results expected to be presented at the American College of Cardiology 2025 Scientific Sessions. In another development, BioCardia has completed enrollment and dosing for the low-dose cohort in its Phase I/II trial of CardiALLO Allogeneic Mesenchymal Cell Therapy. This trial aims to establish the safety and efficacy of the therapy for patients with ischemic heart failure with reduced ejection fraction, who also exhibit elevated markers of heart stress and systemic inflammation. BioCardia’s CEO, Peter Altman, expressed confidence in the CardiALLO MSC program, which could lead to pivotal clinical studies in the U.S. and conditional approval in Japan. The company’s manufacturing process for these cells is expected to be commercially scalable. The first independent safety review for the current trial is scheduled for March 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.